Prakash Deedwania
Cardiovascular Disease · Fresno, CANPI 1467553586
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Amgen at 55.2% of the total. Reporting peaked in 2020 at $15,016 and has fallen 94.6% since, to $809 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 87 payments — averaging $547.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$26K
- Dr.reddy's Laboratories,inc.$11K
- Janssen Scientific Affairs, LLC$6K
- Novartis$3K
- Novo Nordisk$437
- Esperion Therapeutics, Inc.$191
- plus $399 from 5 others
Across 95 payments — averaging $1545.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$74K
- Sanofi US Services Inc.$35K
- Boehringer Ingelheim International GmbH$30K
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
- Regeneron$1K
What the payments were for
- Consulting fees$16,40034%
- Speaking & faculty fees$17,55037%
- Travel & lodging$8,87319%
- Food & beverage$4,57310%
- Education$2451%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 36 | $26,281 |
| Dr.reddy's Laboratories,inc. | 4 | $11,370 |
| Janssen Scientific Affairs, LLC | 8 | $6,330 |
| Novartis | 21 | $2,635 |
| Novo Nordisk | 9 | $437 |
| Esperion Therapeutics, Inc. | 2 | $191 |
| Pfizer | 1 | $123 |
| AstraZeneca | 1 | $100 |
| GSK | 1 | $83 |
| Merck | 3 | $74 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,642 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Fresno
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.